ADCETRIS Drug Profile

Summary for Tradename: ADCETRIS

High Confidence Patents:	41
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for ADCETRIS

Recent Clinical Trials for ADCETRIS

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Jiyan Liu	PHASE1
West China Hospital	PHASE1
Lepu Medical Technology (Beijing) Co., Ltd.	PHASE1

See all ADCETRIS clinical trials

Pharmacology for ADCETRIS

Mechanism of Action	CD30-directed Antibody Interactions
Physiological Effect	Microtubule Inhibition
Established Pharmacologic Class	CD30-directed Immunoconjugate
Chemical Structure	Immunoconjugates

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ADCETRIS Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ADCETRIS Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Seagen Inc.	ADCETRIS	brentuximab vedotin	For Injection	125388		2032-07-25	DrugPatentWatch analysis and company disclosures
Seagen Inc.	ADCETRIS	brentuximab vedotin	For Injection	125388		2037-05-30	DrugPatentWatch analysis and company disclosures
Seagen Inc.	ADCETRIS	brentuximab vedotin	For Injection	125388		2036-05-16	DrugPatentWatch analysis and company disclosures
Seagen Inc.	ADCETRIS	brentuximab vedotin	For Injection	125388		2035-07-17	DrugPatentWatch analysis and company disclosures
Seagen Inc.	ADCETRIS	brentuximab vedotin	For Injection	125388		2038-09-19	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ADCETRIS Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Seagen Inc.	ADCETRIS	brentuximab vedotin	For Injection	125388		2035-05-11	Patent claims search
Seagen Inc.	ADCETRIS	brentuximab vedotin	For Injection	125388		2035-07-16	Patent claims search
Seagen Inc.	ADCETRIS	brentuximab vedotin	For Injection	125388		2036-08-10	Patent claims search
Seagen Inc.	ADCETRIS	brentuximab vedotin	For Injection	125388		2036-12-01	Patent claims search
Seagen Inc.	ADCETRIS	brentuximab vedotin	For Injection	125388		2036-01-27	Patent claims search

International Patents for ADCETRIS

Country	Patent Number	Estimated Expiration
Canada	3148314
Japan	7150793
New Zealand	714044
Brazil	PI0416028
Austria	E512682

Market Dynamics and Financial Trajectory for ADCETRIS (brentuximab vedotin)

Last updated: April 16, 2026

What is the current market position of ADCETRIS?

ADCETRIS (brentuximab vedotin) is a CD30-directed antibody-drug conjugate (ADC) developed by Seagen and Takeda. Approved by the FDA in 2011, it targets CD30-positive hematologic malignancies. Its primary indications include relapsed/refractory Hodgkin lymphoma (HL), systemic anaplastic large cell lymphoma (sALCL), and other mature T-cell lymphomas.

In 2022, ADCETRIS achieved global sales of approximately $850 million, representing consistent revenue growth driven by ongoing approvals and expanding indications.

How do market dynamics influence ADCETRIS’s financial trajectory?

Market growth drivers

1. Expanding Indications:
   Beyond its initial approvals for HL and sALCL, ADCETRIS received FDA approval in 2020 for use with AVD chemotherapy for previously untreated advanced classical Hodgkin lymphoma. This expansion broadens its potential patient base.

2. Global Approvals:
   The drug is marketed in over 60 countries, with approvals in the EU, Japan, and China. China's approval in 2020 is significant, given its growing oncology market.

3. Competition and Alternatives:
   ADCETRIS faces competition from immunotherapies, including PD-1 inhibitors (nivolumab, pembrolizumab), which are increasingly used for similar indications. However, ADCETRIS’s targeted mechanism remains valuable especially in refractory cases.

4. Pricing and Reimbursement:
   High treatment costs (~$10,000 per dose, with a typical course lasting 4-6 cycles) rely heavily on reimbursement policies. NICE (UK) and other health agencies influence pricing strategies across markets.

Market constraints

1. Limited Label Expansion:
   While approvals for frontline HL have supported revenue, further indications are limited, constraining long-term growth.

2. Market Penetration:
   As a second-line therapy, ADCETRIS competes with other treatments. Its adoption rate in some regions is hindered by existing treatment protocols.

3. Patent and Competition Law:
   Patent expiry in scheduled regions could lead to biosimilar or generic competition, affecting pricing and sales.

What is the revenue projection for ADCETRIS?

Historical Sales

Year	Global Sales (USD million)
2019	700
2020	750
2021	800
2022	850

Future Trends

Sales are expected to grow at a compound annual growth rate (CAGR) of approximately 4% over the next five years, driven by:

• Additional approvals in Europe and Asia.
• Potential label expansions for other T-cell lymphomas.
• Increased use in earlier lines of therapy following evolving treatment guidelines.

Assuming moderate market penetration and inflation adjustments, projected sales could reach $1.1 billion by 2027.

How do regulatory and patent developments impact the financial outlook?

1. Regulatory Milestones:
   Positive approvals in new regions or indications provide revenue infusions. Conversely, delays or safety concerns can restrict market access.

2. Patent Status:
   Key patents expire in mid-2025, potentially enabling biosimilar competition. Seagen and Takeda are strategizing to extend market exclusivity through new formulations and indications.

3. Pricing Pressure:
   Governments and payers worldwide have increased scrutiny on drug prices, potentially limiting reimbursement levels and margins.

What are the significant risks facing ADCETRIS’s market and financial trajectory?

• Competitive landscape shift toward immunotherapies and combination regimens.

• Market access limitations in emerging economies due to pricing and healthcare infrastructure.

• Patent expirations spurring biosimilar entry, reducing revenue.

• Emergence of new biomarkers altering the treatment paradigm away from CD30 targeting.

Key financial considerations

Aspect	Details
Revenue (2022)	$850 million globally
Operating margins	Approx. 30–35%, constrained by R&D costs and pricing
R&D investments	~$150 million annually, primarily in new indications and combination therapies
Market cap (2023)	~$10 billion, reflecting steady revenue growth and pipeline prospects

Conclusion

ADCETRIS maintains a solid share within its hematologic oncology niche, driven by global expansion and label extensions. Its financial trajectory benefits from steady revenue growth, but faces headwinds from patent expiry, competitive pressure, and pricing constraints.

---

Key Takeaways

• ADCETRIS generated $850 million in 2022, with growth prospects tied to regional approvals and new indications.
• Market expansion is limited by competition from immunotherapies and emerging treatment standards.
• Patent expiration in mid-2025 could introduce biosimilar competition, impacting revenue.
• Pricing and reimbursement strategies heavily influence profitability.
• Future growth hinges on regulatory milestones, pipeline advancements, and management of competitive risks.

---

FAQs

1. What are the primary indications for ADCETRIS?
Relapsed/refractory Hodgkin lymphoma, systemic anaplastic large cell lymphoma, and other mature T-cell lymphomas.

2. How does ADCETRIS compare with immunotherapies?
While immunotherapies like PD-1 inhibitors have broader applicability, ADCETRIS offers targeted activity in CD30-positive tumors, often used in refractory settings.

3. What is the timeline for patent expiration?
Key patents are scheduled to expire in mid-2025, opening potential pathways for biosimilar competition.

4. Are there ongoing clinical trials for ADCETRIS?
Yes. Trials are exploring combinations with immunotherapies and new indications such as cutaneous T-cell lymphoma.

5. How does market penetration vary across regions?
High in North America and Europe; slower adoption in parts of Asia and Latin America due to pricing and healthcare infrastructure.

---

References

[1] Seagen Inc. (2022). Annual Report.
[2] Takeda Pharmaceutical Company. (2022). Financial Results.
[3] U.S. Food and Drug Administration. (2011). FDA Approval for ADCETRIS.
[4] European Medicines Agency. (2020). Market Authorization.
[5] IQVIA. (2023). Pharmaceutical Market Data.